Search research articles
Contact Us
Filters
Showing results (921-930 of 955) with videos related to
Page
of 96
Sort By:
Breast Cancer Research and Treatment
|
July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Research Square
|
May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Lancet (London, England)
|
March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B Haas, Judith Manola, Robert G Uzzo, et al.
JCO Oncology Practice
|
May 12, 2026
Benefits of Electronic Symptom Monitoring During Cancer Treatment by Age, Sex, Race, and Education (Alliance AFT-39)
Allison M Deal, Yashasvini Sampathkumar, Brenda F Ginos, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 13, 2024
Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp Trial
Elizabeth A Hahn, Stephanie L Pugh, Hien L Lu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 19, 2018
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop
Paul G Kluetz, Bindu Kanapuru, Steven Lemery, et al.
Implementation Science : IS
|
December 3, 2025
Implementation outcomes of a symptom management intervention in ambulatory oncology practices evaluated using a cluster randomized stepped-wedge trial design
Justin D Smith, Katy Bedjeti, Nicola Lancki, et al.
Journal of the National Cancer Institute
|
March 17, 2021
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Lari Wenzel, Kathryn Osann, Chelsea McKinney, et al.
JAMA
|
February 28, 2017
Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment
Susan M Resnick, Alvin M Matsumoto, Alisa J Stephens-Shields, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
Amit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
Page
of 96
Search research articles
Search
Showing results (921-930 of 955) with videos related to
Sort By:
Page
of 96
Breast Cancer Research and Treatment
|
July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Research Square
|
May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Lancet (London, England)
|
March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B Haas, Judith Manola, Robert G Uzzo, et al.
JCO Oncology Practice
|
May 12, 2026
Benefits of Electronic Symptom Monitoring During Cancer Treatment by Age, Sex, Race, and Education (Alliance AFT-39)
Allison M Deal, Yashasvini Sampathkumar, Brenda F Ginos, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 13, 2024
Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp Trial
Elizabeth A Hahn, Stephanie L Pugh, Hien L Lu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 19, 2018
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop
Paul G Kluetz, Bindu Kanapuru, Steven Lemery, et al.
Implementation Science : IS
|
December 3, 2025
Implementation outcomes of a symptom management intervention in ambulatory oncology practices evaluated using a cluster randomized stepped-wedge trial design
Justin D Smith, Katy Bedjeti, Nicola Lancki, et al.
Journal of the National Cancer Institute
|
March 17, 2021
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Lari Wenzel, Kathryn Osann, Chelsea McKinney, et al.
JAMA
|
February 28, 2017
Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment
Susan M Resnick, Alvin M Matsumoto, Alisa J Stephens-Shields, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
Amit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
Page
of 96